This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the Phase 2 X-NOVA clinical trial data on Xenon's XEN1101 in patients with Major Depressive Disorder

Ticker(s): XENE

Who's the expert?

Institution: Stanford University

  • Founder and Director of the Stanford Center for Neuroscience in Women’s Health,
  • Currently manages 45 patients with MDD and has treated hundreds of patients with premenstrual dysphoric disorder
  • Clinical focus on Neuropsychology for Anxiety, Depression, and Women's Health; Research focus on investigating the neuroscience of stress, specifically biomarkers of cellular aging in executives and gender differences in stress response.

Interview Goal
This interview will focus on the standard of care and the potential of  XEN1101 as part of treatment for MDD  in light of the Phase 2 clinical trial data from Xenon Pharmaceuticals

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.